Published on GHDx (https://ghdx.healthdata.org)

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study

General Info

Geography 
China (CHN)
Hubei
Time period covered 
January, 2020 - December, 2020
Data type
Scientific literature
Keywords 
COVID-19

Citation

Authors 
He Z, Ren L, Yang J, Guo L, Feng L, Ma C, Wang X, Leng Z, Tong X, Zhou W, Wang G, Zhang T, Guo Y, Wu C, Wang Q, Liu M, Wang C, Jia M, Hu X, Wang Y, Zhang X, Hu R, Zhong J, Yang J, Dai J, Chen L, Zhou X, Wang J, Yang W, Wang C
Journal 
Lancet
Pages 
1075-1084
Publication year 
2021
Suggested citation 
He Z, Ren L, Yang J, Guo L, Feng L, Ma C, Wang X, Leng Z, Tong X, Zhou W, Wang G, Zhang T, Guo Y, Wu C, Wang Q, Liu M, Wang C, Jia M, Hu X, Wang Y, Zhang X, Hu R, Zhong J, Yang J, Dai J, Chen L, Zhou X, Wang J, Yang W, Wang C. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021; 397(10279): 1075-1084.
Source URL:https://ghdx.healthdata.org/record/seroprevalence-and-humoral-immune-durability-anti-sars-cov-2-antibodies-wuhan-china#comment-0